Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04093388 · ClinicalTrials.gov registry record · NA

Self-Collection of the Pap Smear as Agency: A Novel Way to Improve Refractory Low Cervical Cancer Screening Rates in Rural Alabama

A NA study of Cervical Cancer, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
NA
Development phase
250
Enrollment target
3
Study locations

NCT04093388 is a NA study of Cervical Cancer that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 250 participants, below the 569-participant average among 144 other Cervical Cancer trials with a reported enrollment target (56% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04093388, a NA study of Cervical Cancer, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
NA
Development phase
250 participants
Enrollment target
3
Study locations

Study Summary

The purpose of the study is to find out if a self-administered (by the patient) Papanicolaou (Pap) smear is as accurate as a traditional Pap smear administered by a healthcare provider.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Self-PAP
  • DIAGNOSTIC_TEST Traditional Pap smear

Study Locations (3)

Alabama

  • Cahaba Medical Care - West End - Birmingham
  • Cahaba Medical Care - Ensley - Birmingham
  • Cahaba Medical Care - Centreville

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2021-04-26
Est. Completion 2026-06-30
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT04093388

The ClinicalTrials.gov registry entry for NCT04093388 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 569-participant average among 144 other Cervical Cancer trials with a reported enrollment target (56% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which Self-PAP is the first listed.

NCT04093388 reports 3 study locations spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT04093388 about?

NCT04093388 is a clinical study titled "Self-Collection of the Pap Smear as Agency: A Novel Way to Improve Refractory Low Cervical Cancer Screening Rates in Rural Alabama". The purpose of the study is to find out if a self-administered (by the patient) Papanicolaou (Pap) smear is as accurate as a traditional Pap smear administered by a healthcare provider.

What is the current status of trial NCT04093388?

This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2021-04-26. Estimated completion is 2026-06-30.

What conditions does trial NCT04093388 study?

This clinical trial studies the following conditions: Cervical Cancer.

What interventions are being tested in trial NCT04093388?

The interventions under investigation include: Self-PAP (DIAGNOSTIC_TEST), Traditional Pap smear (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04093388?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04093388 being conducted?

This trial has 3 study locations across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cervical Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.